Investment analysts at Wedbush assumed coverage on shares of Mirna Therapeutics (NASDAQ:SYBX) in a research report issued on Monday. The brokerage set an “outperform” rating and a $20.00 price target on the biotechnology company’s stock. Wedbush’s target price would suggest a potential upside of 96.66% from the company’s previous close.

SYBX has been the topic of several other research reports. ValuEngine lowered shares of Mirna Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Zacks Investment Research lowered shares of Mirna Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, November 22nd. Finally, Leerink Swann started coverage on shares of Mirna Therapeutics in a report on Tuesday, September 19th. They set an “outperform” rating and a $25.00 target price on the stock. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $19.67.

Mirna Therapeutics (NASDAQ SYBX) opened at $10.17 on Monday. Mirna Therapeutics has a twelve month low of $8.76 and a twelve month high of $23.00.

COPYRIGHT VIOLATION WARNING: “Wedbush Begins Coverage on Mirna Therapeutics (SYBX)” was posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/11/28/mirna-therapeutics-sybx-outperform-rating-reaffirmed-at-wedbush.html.

Mirna Therapeutics Company Profile

Synlogic, Inc, formerly Mirna Therapeutics, Inc, is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).

Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.